Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) received National Medical Products Administration (NMPA) approval to initiate a clinical study of HRS9531 for reducing major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease (ASCVD). The innovative dual GIPR/GLP-1R agonist, already approved for weight reduction and chronic kidney disease trials, now targets cardiovascular outcomes – a globally unprecedented indication for this drug class, with potential benefits via weight loss, glycemic control, and direct mechanisms.
Tirzepatide’s GIP component may enhance lipid metabolism and vascular benefits vs. pure GLP-1; HRS9531 tests this hypothesis in dedicated ASCVD outcomes trial
Hengrui Metabolic Franchise
HRS9531 anchors GLP-1/GIP pipeline alongside oral formulations; cardiovascular outcomes indication expands beyond weight loss/CKD into hard endpoint differentiation
Global First-Mover
No approved GIPR/GLP-1R agonist for ASCVD MACE reduction – success would establish cardiovascular outcomes class leadership
Trial Design
Likely Phase IIb/III cardiovascular outcomes study (3–5 year follow-up) – requires large patient population (n=5,000–10,000) and event-driven endpoint
Clinical Timeline: Phase II 2026–2027; Phase III CVOT initiation 2028; potential approval 2031–2032 assuming positive MACE benefit
Commercial Potential: ASCVD indication adds RMB 5–10 billion to HRS9531 peak sales (weight loss + CKD + cardiovascular); global licensing opportunity $5+ billion given differentiated outcomes data
Forward‑Looking Statements This brief contains forward‑looking statements regarding cardiovascular outcomes trial design, MACE endpoint achievement, and regulatory pathway for HRS9531 in ASCVD. Actual results may differ due to long trial duration, competitive dynamics with semaglutide/tirzepatide cardiovascular data, and reimbursement requirements for cardiovascular risk reduction indications.-Fineline Info & Tech
By Fineline Cube